Long-Acting Glucose-Dependent Insulinotropic Polypeptide Ameliorates Obesity-Induced Adipose Tissue Inflammation

Chen Varol, Isabel Zvibel, Lior Spektor, Fernanda Dana Mantelmacher, Milena Vugman, Tamar Thurm, Marian Khatib, Elinor Elmaliah, Zamir Halpern and Sigal Fishman

J Immunol 2014; 193:4002-4009; Prepublished online 12 September 2014;
doi: 10.4049/jimmunol.1401149
http://www.jimmunol.org/content/193/8/4002

Supplementary Material
http://www.jimmunol.org/content/suppl/2014/09/12/jimmunol.1401149.DCSupplemental

References
This article cites 38 articles, 11 of which you can access for free at:
http://www.jimmunol.org/content/193/8/4002.full#ref-list-1

Why The JI? Submit online.
• Rapid Reviews! 30 days* from submission to initial decision
• No Triage! Every submission reviewed by practicing scientists
• Fast Publication! 4 weeks from acceptance to publication

*average

Subscription
Information about subscribing to The Journal of Immunology is online at:
http://jimmunol.org/subscription

Permissions
Submit copyright permission requests at:
http://www.aai.org/About/Publications/JI/copyright.html

Email Alerts
Receive free email-alerts when new articles cite this article. Sign up at:
http://jimmunol.org/alerts
Long-Acting Glucose-Dependent Insulinotropic Polypeptide Ameliorates Obesity-Induced Adipose Tissue Inflammation

Chen Varol,* Isabel Zvibel,* Lior Spektor,* Fernanda Dana Mantelmacher,* Milena Vugman,* Tamar Thurhm,* Marian Khatib,† Elinor Elmaliah,* Zamir Halpern,* and Sigal Fishman*

Obesity induces low-grade chronic inflammation, manifested by proinflammatory polarization of adipose tissue innate and adaptive resident and recruited immune cells that contribute to insulin resistance (IR). The glucose-dependent insulinotropic polypeptide (GIP) is an incretin hormone that mediates postprandial insulin secretion and has anabolic effects on the adipose tissue. Importantly, recent evidence suggested that GIP is a potential suppressor of inflammation in several metabolic models. In this study, we aimed to investigate the immunoregulatory role of GIP in a murine model of diet-induced obesity (DIO) using the long-acting GIP analog [d-Ala²]GIP. Administration of [d-Ala²]GIP resulted in adipocytes of increased size, increased levels of adipose tissue lipid droplet proteins, indicating better lipid storage capacity, and reduced adipose tissue inflammation. Flow cytometry analysis revealed reduced numbers of inflammatory Ly6Chi monocytes and F4/80hi macrophages, associated with IR. In addition, [d-Ala²]GIP reduced adipose tissue infiltration of IFN-γ-producing CD8⁺ and CD4⁺ T cells. Furthermore, [d-Ala²]GIP treatment induced a favorable adipose tissue adipokine profile, manifested by a prominent reduction in key inflammatory cytokines (TNF-α, IL-1β, IFN-γ) and chemokines (CCL2, CCL8, and CCL5) and an increase in adiponectin. Notably, [d-Ala²]GIP also reduced the numbers of circulating neutrophils and proinflammatory Ly6Chimacrophages in mice fed regular chow or a high-fat diet. Finally, the beneficial immune-associated effects were accompanied by amelioration of IR and improved insulin signaling in liver and adipose tissue. Collectively, our results describe key beneficial immunoregulatory properties for GIP in DIO and reveal that its augmentation ameliorates adipose tissue inflammation and improves IR. The Journal of Immunology, 2014, 193: 4002–4009.
However, GIP may have other extrapancreatic beneficial effects. Specifically, in the adipose tissue, GIP potentiates the anabolic effects of insulin by increasing triglyceride (TG) uptake via lipoprotein lipase and, thus, increases lipid storage (20). In agreement with this, GIP inhibits adipose tissue lipolysis both in vitro and in vivo (21). In addition, GIP induces adipocyte maturation and differentiation (22).

The in vivo anti-inflammatory effect of GIP was suggested by studies showing reduced adipose tissue inflammatory cytokines in GIP-overexpressing transgenic mice (23) and by reduced atherosclerosis following administration of exogenous GIP (24, 25). Nevertheless, the role of GIP in adipose tissue inflammation with respect to mobilization and function of immune cells has not been thoroughly investigated. The present study investigated the in vivo effect of short-term or long-term administration of a long-lasting GIP analog, [d-Ala²]GIP (26, 27), on the development of adipose tissue inflammation and immune cell recruitment in a murine DIO model. Our results show that administration of [d-Ala²]GIP significantly reduced the levels of circulating proinflammatory neutrophils, as well as Ly6C⁺ monocytes and their descendants, in the epididymal adipose tissue. Moreover, we report significant reduction in the accumulation of previously described proinflammatory CD11c⁺ ATMs, together with reduced infiltration of IFNγ⁺ CD8⁺ and CD4⁺ T cells. The beneficial anti-inflammatory effect of [d-Ala²]GIP was further highlighted by the reduction in various inflammatory cytokines and chemokines and increased adiponectin expression. Finally, these immunological effects were accompanied by enhanced adipocyte storage capacity and improvement in metabolic parameters.

Materials and Methods

Animals, DIO, and [d-Ala²]GIP administration

C57BL/6 male mice (5 wk old, 19–21 g) were fed regular chow (RC) or a high-fat diet (HFD; 60% calories from fat; Research Diets, cat. no. D12492) for 10 wk (short regimen) or 14 wk (long regimen), and they received a single daily i.p. injection of human [d-Ala²]GIP (0.12 µg g body weight) (synthesized by Biosynthesis, Lewisville, TX) or vehicle (saline) during the last 2 wk (short regimen) or 8 wk (long regimen). Of note, previous studies used native human GIP and [d-Ala²]GIP in rodent models (24–27). Animals had unrestricted access to food and water, were housed in temperature and humidity-controlled rooms, and were kept on a 12-h light/dark cycle. Thirty minutes before they were sacrificed, all mice received an i.p. injection of insulin (0.75 U/kg body weight). Blood was obtained from the left ventricle of the mice before they were sacrificed, all mice received an i.p. injection of insulin (0.75 U/kg body weight), and then stained for the intracellular expression of IFNγ and IFN-γ. Cells were stained for surface markers of T cells, fixed and permeabilized, and then stained for the intracellular expression of IFN-γ and IL-17A. Cells were analyzed with a FACSCanto II or LSR Fortessa flow cytometer (Becton Dickinson) using FACS DIVA (Becton Dickinson) or FlowJo software.

Protein immunoblots (Western blots)

Total protein was extracted from the liver using the EZ-RNA kit (Biological Industries, Bet Haemek, Israel) and from adipose tissue using the RNase Lipid tissue kit (QIAGEN), and 200 ng–2 µg total RNA was reverse-transcribed using M-MLV (Promega, Madison, WI). qRT-PCR was performed using Absolute Blue qPCR SYBR Green ROX mix (Thermo Fisher Scientific, Epsom, Surrey, U.K.) in the Corbett rotor light cycler (Corbett Robotics, Brisbane, Australia).

The results are presented as mean ± SEM. Statistical significance was assessed using a two-tailed Student t test, with p values < 0.05 considered significant.

Results

Treatment with [d-Ala²]GIP enhances adipose tissue lipid storage capacity along with amelioration of inflammation

To investigate the role of GIP in a metabolic model, we implemented the well-characterized murine DIO model of diet-induced IR. Our strategic experimental approach was based on augmentation of physiological GIP levels by injection of the long-lasting GIP agonist [d-Ala²]GIP (26, 27) during the last 8 wk of a 14-wk HFD regimen. We started the HFD regimen in 5-wk-old mice, since animals of the same age were used in a previous study that thoroughly documented changes in ATMs and T cell populations from 2 to 20 wk HFD feeding compared with RC feeding (14).

We did not find any difference between mice fed HFD that received vehicle or [d-Ala²]GIP with respect to food intake and total
body and visceral fat weight (Table I). Obesity is characterized by fat hypertrophy and increased adipocyte area, accompanied by increased infiltration of immune cells into the visceral fat depots. Indeed, H&E staining of epididymal fat tissue sections from mice fed RC or HFD revealed dramatic immune cell infiltration and increased adipocyte area under DIO conditions (Fig. 1A). Strikingly, there was a 2-fold increase in the adipocyte area of mice receiving \([\text{d-Ala}^2]\text{GIP}\) treatment, yet substantially reduced immune cell infiltration, in comparison with mice receiving HFD and vehicle (Fig. 1A, 1B). Previous studies established that GIP induces adipose tissue lipogenesis and TG uptake (20). Importantly, to our knowledge, we show for the first time the positive effect of \([\text{d-Ala}^2]\text{GIP}\) treatment on the gene expression of lipid droplet proteins PLIN1, CIDEA, and CIDEC, as well as their transcription factor regulator, PPARγ (Fig. 1C). In particular, there was a 2-fold increase in the expression of CIDEC, which was positively associated with insulin sensitivity in obese human patients (30) (Fig. 1C). Similar effects on increased expression of genes for lipid droplet proteins also were observed after short-term \([\text{d-Ala}^2]\text{GIP}\) treatment during the last 2 wk of the 10-wk HFD regimen (Supplemental Fig. 1C). Lastly, we determined the expression levels of GIPR within the adipose tissue after long-term treatment with \([\text{d-Ala}^2]\text{GIP}\) and observed no significant change in \([\text{d-Ala}^2]\text{GIP}\)-treated mice at either the mRNA (Fig. 1C) or protein (Supplemental Fig. 2) level, excluding the possibility of desensitization due to the \([\text{d-Ala}^2]\text{GIP}\) treatment.

### Table I. Body parameters in mice after a 14-wk HFD or HFD with \([\text{d-Ala}^2]\text{GIP}\)

<table>
<thead>
<tr>
<th></th>
<th>HFD</th>
<th>HFD + ([\text{d-Ala}^2]\text{GIP})</th>
</tr>
</thead>
<tbody>
<tr>
<td>Body weight (g)</td>
<td>38.2 ± 1.6</td>
<td>38.1 ± 0.7</td>
</tr>
<tr>
<td>Food intake (kcal/mouse/d)</td>
<td>11.4 ± 1.1</td>
<td>11.7 ± 1.2</td>
</tr>
<tr>
<td>Liver (g)</td>
<td>1.5 ± 0.1</td>
<td>1.2 ± 0.05*</td>
</tr>
<tr>
<td>Epididymal fat (g)</td>
<td>2.4 ± 0.1</td>
<td>2.5 ± 0.1</td>
</tr>
<tr>
<td>Total fat (g)</td>
<td>3 ± 0.1</td>
<td>3.3 ± 0.18</td>
</tr>
<tr>
<td>Percentage fat/body weight</td>
<td>7.9 ± 0.3</td>
<td>8.6 ± 0.4</td>
</tr>
</tbody>
</table>

Five-week-old C57BL/6 male mice received HFD for 14 wk; during the last 8 wk, they received daily i.p. injections of saline (n = 8) or \([\text{d-Ala}^2]\text{GIP}\) (0.12 μg/g body weight) (n = 8).

\*p < 0.05.

### FIGURE 1. \([\text{d-Ala}^2]\text{GIP}\) administration increases adipocyte storage capacity in DIO. (A) Representative H&E-stained paraffin sections of epididymal fat from mice fed RC, HFD for 14 wk and saline administration (HFD), or HFD for 14 wk with \([\text{d-Ala}^2]\text{GIP}\) administration. Notice the impressive reduction in infiltration of immune cells and increase in adipocyte area in the \([\text{d-Ala}^2]\text{GIP}\)-treated mice. (B) Adipocyte area calculated from epididymal fat of mice fed RC or HFD for 14 wk with vehicle or \([\text{d-Ala}^2]\text{GIP}\) injections. Data are mean ± SEM. (C) Adipose tissue mRNA expression of metabolic enzymes, adipocyte markers of differentiation, and lipid droplet proteins from mice that received HFD or HFD with \([\text{d-Ala}^2]\text{GIP}\). Expression of the genes was detected by qRT-PCR and normalized to RPLPO. Data are mean ± SEM (n = 8/group). \*p < 0.05.
mice on the 14-wk HFD. Flow cytometry analysis of peripheral blood demonstrated significantly reduced levels of circulating neutrophils characterized as Gr1(Ly6G/C)hiCD1152CD11b+ (Fig. 3A). In addition, [d-Ala2]GIP treatment reduced the numbers of both Ly6C++ and Ly6C++ CD115+ blood monocyte subsets, but it had no effect on the levels of CD3+ T cells (Fig. 3A). Moreover, short treatment (1 wk) with [d-Ala2]GIP in mice fed RC also significantly reduced the numbers of circulating neutrophils (Fig. 3B), implying that [d-Ala2]GIP regulates neutrophil egress from bone marrow (BM), irrespective of the metabolic state of the mice. In addition, BM flow cytometry analysis in the DIO model revealed increased numbers of neutrophils in the [d-Ala2]GIP group, with no significant changes in Ly6C++ monocytes or their precursors, macrophage dendritic cell precursor cells,
with the latter characterized as CD11b<sup>-</sup>Gr1(Ly6C/G)<sup>-</sup>cKit<sup>hi</sup>CD115<sup>+</sup>CD135<sup>+</sup> (Fig. 3C). Collectively, these results reveal that augmentation of GIP levels specifically reduces the numbers of proinflammatory circulating innate immune cells.

FIGURE 3. [d-Ala<sup>2</sup>]GIP administration reduces the number of circulating BM-derived monocytes and neutrophils in mice after HFD and RC. (A) Representative flow cytometry images show the gating strategy used to define circulating immune cells in mice fed a 14-wk HFD (upper panels). Numbers of circulating T cells, neutrophils, and Ly6C<sup>hi</sup> and Ly6C<sup>lo</sup> monocytes collected from mice on a 14-wk HFD that were treated with saline or [d-Ala<sup>2</sup>]GIP during the last 8 wk (lower panel). Data are mean ± SEM (n = 8/group), normalized per 50 µl of peripheral blood. (B) Numbers of peripheral blood immune cells collected from mice on RC that were treated with saline or [d-Ala<sup>2</sup>]GIP for 7 d. Data are mean ± SEM (n = 8/group), normalized per 50 µl of peripheral blood. (C) Numbers of BM monocytes and neutrophils, as well as macrophage dendritic cell precursor cells (MDP), in mice fed RC or a 14-wk HFD and that received saline or [d-Ala<sup>2</sup>]GIP treatment. *p < 0.05.

FIGURE 4. [d-Ala<sup>2</sup>]GIP administration reduces adipose tissue inflammatory chemokines and cytokines in a DIO model. The mRNA expression of recruitment chemokines (A) and inflammatory cytokines (B) was assessed by qRT-PCR in epididymal fat of mice on a 14-wk HFD and treated with saline or [d-Ala<sup>2</sup>]GIP. Data are mean ± SEM (n = 8/group). (C) Serum adiponectin levels in mice on a 14-wk HFD that received saline or [d-Ala<sup>2</sup>]GIP. Data are mean ± SEM (n = 8/group). *p < 0.05.
Treatment with [d-Ala²]GIP attenuates adipose tissue expression of inflammatory chemokines and cytokines in DIO

Monocyte recruitment from BM to the inflamed adipose tissue is mediated via CCR2 through binding to CCL5 or CCL8 chemokines, which are secreted by adipocytes or local immune cells (9, 12). In agreement with the reduction in Ly6ch⁰ monocytes in the adipose tissue (Fig. 2A), [d-Ala²]GIP treatment significantly reduced the expression of CCL5 and CCL8 within the epididymal adipose tissue (Fig. 4A). In line with the observed reduction in T cell recruitment after [d-Ala²]GIP treatment (Fig. 2B), we also saw a significant reduction in the T cell recruitment chemokine CCL5 (Fig. 4A). A similar reduction in the expression of recruitment chemokines was observed following short-term [d-Ala²]GIP treatment (Supplemental Fig. 1A).

The inflammatory link between TNF-α and IL-1β and obesity-induced IR is well established (31–33). In this study, we showed, in a DIO model, that treatment with [d-Ala²]GIP significantly ameliorated adipose tissue inflammation, manifested by a significant reduction in the expression of TNF-α and IL-1β after long (Fig. 4B) and short (Supplemental Fig. 1B) [d-Ala²]GIP treatment. Osteopontin and fractalkine, both involved in the immune-regulation of IR, also were significantly lower in adipose tissue of [d-Ala²]GIP mice (Fig. 4B). In accordance with reduced numbers of IFN-γ-producing T cells following [d-Ala²]GIP treatment, there also was a significant reduction in adipose tissue mRNA levels of IFN-γ (Fig. 4B). Finally, we showed previously in rat and human ex vivo explants that [d-Ala²]GIP administration significantly increased the expression of adiponectin, a well-known insulin-sensitizing adipokine (33). Strengthening these results, in this study we demonstrate in in vivo settings that GIP augmentation resulted in the profound increase of adipose tissue adiponectin mRNA in DIO after both long-term (Fig. 4B) and short-term [d-Ala²]GIP administration (Supplemental Fig. 1B). The serum adiponectin levels also increased by 20% in mice fed HFD that received [d-Ala²]GIP (Fig. 4C). As expected, mRNA levels of resistin, a known target of GIP activation, also were elevated in the [d-Ala²]GIP–treated group fed HFD (Fig. 4B).

[d-Ala²]GIP treatment improves insulin sensitivity in DIO

The insulin tolerance test (ITT) assay revealed improved insulin sensitivity in mice on the HFD treated with [d-Ala²]GIP compared with mice that received vehicle only, which was manifested by increased clearance of serum glucose (Fig. 5A). The increased insulin sensitivity following [d-Ala²]GIP administration was corroborated by the significantly reduced area under the curve, calculated from the concentrations of glucose versus time (Fig. 5B). The improved insulin sensitivity induced by the long-term [d-Ala²]GIP administration was further confirmed by the increased expression of the insulin-signaling key mediator pAkt, both in adipose tissue and in liver (Fig. 5C, 5D). However, although short-term [d-Ala²]GIP treatment in DIO induced better glucose tolerance test, as exhibited by lower plasma glucose levels after high-dose IP glucose administration, it was not sufficient to improve insulin sensitivity, as determined by ITT (Supplemental Fig. 1D).

Ex vivo treatment of human obese patient–derived mesenteric adipose tissue with [d-Ala²]GIP reduces expression of inflammatory cytokines

Adipose tissue explants obtained from obese patients were treated ex vivo with [d-Ala²]GIP for 24 h and assessed for the expression of inflammatory cytokines and chemokines by qRT-PCR. We observed significant reductions in IL-6 and IL-1β and CCL8 mRNA, as well as a slight reduction in mRNA expression of CCL2 and CCL5, in the [d-Ala²]GIP–treated explants (Fig. 6).

Interestingly, progranulin, a newly described adipokine shown to be increased in serum of patients with IR (34), also was reduced by the [d-Ala²]GIP treatment (Fig. 6).

Discussion

The present study investigated the effects of GIP at the interface between the metabolic and immunological arenas. We chose to focus on a 14-wk HFD regimen, a time period by which the mice are hyperglycemic and have developed profound IR and DIO-associated chronic inflammatory response involving both adaptive and innate immunity. The inflammatory chemokine and cytokine expression was reduced by GIP treatment in the adipose tissue and in the blood, as well as in the liver. This was accompanied by increased adiponectin and reduced proinflammatory cytokines in the DIO model. The findings provide evidence for an inflammatory link between TNF-α and IL-1β and obesity-induced IR, and support the idea that GIP induces a metabolic state that is associated with a reduced activation/inflammation, and thus with an improved insulin sensitivity.
and innate immunity (14). The [d-Ala²]GIP injections were initiated 6 wk after starting HFD, based on a previous study indicating this time as the beginning of the chronic inflammatory response (14). We show that GIP significantly reduced the accumulation of ATM subpopulations, as well as of adipose tissue IFN-γ-producing CD8⁺ and CD4⁺ T cells, which was accompanied by a significant reduction in various proinflammatory chemokines and cytokines. In addition, [d-Ala²]GIP reduced the numbers of proinflammatory circulating monocytes and neutrophils. Importantly, all of these effects may explain the overall improved insulin sensitivity of the [d-Ala²]GIP–treated mice. Our data suggest two possible mechanisms involved in GIP anti-inflammatory effects: reduced egress of monocytes and neutrophils from the BM or increased adipose tissue lipid storage capacity, resulting in reduced adipose tissue inflammation.

Adipose tissue from obese mice and humans is infiltrated with large numbers of macrophages, which play an initial dominant role in the development of systemic IR, glucose tolerance, and type 2 diabetes (6–12). In the current study, long-term treatment with [d-Ala²]GIP significantly reduced the levels of three distinct ATM subsets: F4/80hi CD11bhiCD11c⁻ resident ATMs, infiltrating Ly6C⁺CD11b⁺ monocytes, and F4/80⁺CD11c⁺ ATMs. Previous studies documented that the F4/80⁺CD11c⁺ ATMs accumulate in adipose tissue during DIO by a CCR2-nondependent mechanism and express various inflammatory cytokines. Indeed, ablation of this population reversed HFD-induced IR (11). Furthermore, treatment with [d-Ala²]GIP greatly reduced the adipose tissue infiltration by both CD8⁺ and CD4⁺ T cells and, specifically, IFN-γ-producing cells. Notably, obesity is associated with a reduction in anti-inflammatory Foxp3⁺ regulatory T cells (13), in parallel with an increase in the accumulation of proinflammatory CD8⁺ T cells and Th1 CD4⁺ T cells in adipose tissue (14, 15). T cell–derived IFN-γ is a pivotal mediator of the obesity-induced chronic inflammatory response, and obese IFN-γ–deficient mice have significantly reduced adipose tissue expression of inflammatory mediators, such as TNF-α and CCL5, decreased inflammatory cell accumulation, and better glucose tolerance (16).

Continuous elevation of GIP levels in DIO reduced the levels of peripheral blood neutrophils and Ly6C⁺ and Ly6C⁻ monocytes. Of note, similar effects were obtained in mice on RC with short- and medium-term [d-Ala²]GIP treatment, indicating that GIP may be involved in immune-regulatory pathways responsible for the development and migration of BM-derived neutrophils and monocytes, independently of the metabolic status of the organism. GIPR is present in the bone, both on osteoclasts and osteoblasts, and mediates GIP regulation of bone turnover, suggesting that GIP may act directly in the bone to prevent egress of immune cells (35). A second mechanism by which GIP may induce egress of immune cells from BM is via increased formation of corticoste- rone (36), a hormone that negatively regulates BM hematopoietic progenitor cells (37). Another possible mechanism through which GIP may interfere with the recruitment of CCR2⁺ monocytes from the BM is via reduced adipose tissue expression of the CCR2 chemokines CCL5 and CCL8 (Fig. 4). Lastly, a recent article (38) described the inflammasome and IL-1β as the link between adipose tissue obesity-induced inflammation and myelopoiesis in the BM, compatible with our data showing reduced IL-1β in GIP-treated adipose tissue (Fig. 4).

In addition to the immune-regulatory effects of [d-Ala²]GIP administration, we observed beneficial metabolic outcomes that may be attributed, in part, to the anti-inflammatory effects. To our knowledge, we show for the first time that GIP significantly increases the expression of the lipid droplet proteins CIDEC, CIDEC, and PLIN1 (Fig. 1). These proteins greatly enhance lipid droplet size, allowing greater adipose tissue lipid deposition and, thus, protecting other tissues from lipid accumulation (3). Indeed, the expression of lipid droplet proteins in adipose tissue of body mass index–matched obese humans positively correlates with insulin sensitivity (30). Thus, the GIP-governed increased lipid storage capacity of adipose tissue may reduce apoptosis and necrosis of adipocytes and attenuate the adipose tissue inflammatory cascade.

Finally, our results with human ex vivo explants strengthen the in vivo effects observed with [d-Ala²]GIP in the DIO model and demonstrate direct anti-inflammatory effects of GIP on human adipose tissue. Especially interesting is the reduction of IR-associated progranulin, which was shown to be increased in adipose tissue following HFD and to enhance IR by increasing adipocyte tissue IL-6 expression (34). In conclusion, we demonstrated the effects of long-term GIP augmentation on circulating and adipose tissue innate and adaptive immune cells, culminating in an improved inflammatory and metabolic profile.

Acknowledgments
We thank M. Kaplan, DVM for excellent care of the animals.

Disclosures
The authors have no financial conflicts of interest.

References


The Journal of Immunology 4009

Downloaded from http://www.jimmunol.org/ by guest on August 14, 2021